1875: Katharine McCormick Born

On This Day in Health: August 27, 1875

Katharine Dexter McCormick was born in Dexter, Michigan, on August 27, 1875. She studied biology at the Massachusetts Institute of Technology and graduated in 1904, becoming one of the institute’s earliest women science graduates. McCormick also became a prominent suffrage organizer and later worked closely with birth-control advocate Margaret Sanger. Her wealth, scientific training, and willingness to challenge restrictions allowed her to support projects that universities, governments, and companies were reluctant to fund, especially research aimed at giving women direct control over contraception.

In the early 1950s, Sanger introduced McCormick to reproductive biologist Gregory Pincus at the Worcester Foundation for Experimental Biology. McCormick supplied most of the private funding for work by Pincus, Min Chueh Chang, John Rock, Celso-Ramón García, Edris Rice-Wray, and other researchers. She did more than sign checks: she followed the science, visited the laboratory, pressed for progress, and helped sustain a program through animal studies, formulation, and clinical testing. The U.S. Food and Drug Administration approved Enovid for contraception in 1960.

The pill gave many women an effective method they could use independently of a sexual partner at the time of intercourse, changing family planning, education, employment, and medical practice. Its development also involved serious ethical failures and inequalities. Large trials in Puerto Rico enrolled women who were told the product prevented pregnancy but were not adequately informed that it was experimental or about all risks. Early formulations contained much higher hormone doses than later pills and produced substantial side effects. Celebrating access requires acknowledging the women whose participation was shaped by unequal power and incomplete consent.

McCormick later supported housing for women at MIT, medical education, Planned Parenthood, and biomedical research. Her birthday highlights philanthropy as an active force in health innovation: a determined funder can create room for research excluded by conventional institutions. It also raises questions about who sets research priorities, who accepts risk, and who receives benefits. Oral contraceptives have continued to change in dose and formulation, and they are not suitable for every person. Their public-health significance lies in expanded reproductive choice, while safe use depends on informed consent, accurate counseling, access, and respect for each patient’s circumstances and decisions. Access to contraception also changes health beyond pregnancy prevention. Clinicians may prescribe combined or progestin-only pills for menstrual symptoms and other conditions, while patients choose among many reversible and permanent methods. Choice is meaningful only when cost, confidentiality, disability access, language, and freedom from coercion allow people to accept or decline a method.